
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd has positioned itself uniquely in the regenerative and aesthetic medicine market through strategic partnerships, including an expanded agreement with STEMCELL Technologies, which enhances the supply chain for its rhCollagen product and bolsters North American growth opportunities. The company's advancements in 3D bioprinting, particularly with Collink.3D, demonstrated superior tissue formation capabilities compared to traditional products, potentially setting the stage for a first-to-market advantage in a burgeoning market. Additionally, the establishment of a U.S.-based logistics center is expected to positively impact sales of BioInk and rhCollagen, while a recent distribution agreement in Poland aims to expand the reach of its Vergenix STR product across Europe.
Bears say
CollPlant Biotechnologies Ltd has experienced challenges in achieving consistent revenue growth, as indicated by fluctuating income from its diverse product lines, including BioInk and rhCollagen. The company’s dependence on a limited number of markets, particularly the U.S. and Europe, raises concerns about its vulnerability to regional economic fluctuations and competition in the regenerative medicine sector. Additionally, the financial performance is hindered by high operational costs associated with research and development, which may affect profitability in the near term.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares